Health Condition 1: null- POST MENOPAUSAL WOMEN- (SURGICALLY AND NATURALLY) WITH MENOPAUSAL SYMPTOMS.
Conditions
Interventions
Intervention1: TIBOLONE: TIBOLONE 2.5 MG DAILY IN POST MENOPAUSAL WOMEN (SURGICALLY OR NATURALLY) WITH DISTRESSING MENOPAUSAL SYMPTOMS NEEDING HORMONE REPLACEMENT THERAPY.THERAPY TO BE CONTINUED FOR 6
Sponsors
SCDAS MEMORIAL MEDICAL AND RESEARCH CENTER
Eligibility
Inclusion criteria
Inclusion criteria: MENOPAUSAL WOMEN WITH DISTRESSING MENOPAUSAL SYMPTOMS NEEDING HORMONE REPLACEMENT THERAPY WILL BE TREATED WITH TIBOLONE 2.5 MG DAILY TABLETS. AT BASELINE SERUM CALCIUM AND 25-HYDROXY VITAMIN D3 LEVELS WILL BE MEASURED AND AGAIN THE TESTS WILL BE REPEATED AFTER 6 MONTHS WHILE ON TIBOLONE TREATMENT.
Exclusion criteria
Exclusion criteria: CASES WITH HISTORY OF INTAKE OF OTHER FORMS OF HORMONE REPLACEMENT THERAPIES IN THE PRECEDING 3 MONTHS;CASES ALREADY ON CALCIUM AND VITAMIN D3 SUPPLEMENTATION;CASES WITH UNCONTROLLED HYPERTENSION AND DIABETES; CASES WITH HYPERSENSITIVITY TO TIBOLONE.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CHANGE IN SERUM CALCIUM AND 25-HYDROXY VITAMIN D3 LEVELSTimepoint: 6 (SIX) MONTHS AFTER TREATMENT | — |
Secondary
| Measure | Time frame |
|---|---|
| ANY SIDE EFFECTS NOTED WITH TIBOLONE.Timepoint: WITHIN 6 MONTHS OF TREATMENT | — |
Countries
India
Contacts
Public ContactSUDHINDRA MOHAN BHATTACHARYA
KPC MEDICAL COLLEGE
Outcome results
None listed